دورية أكاديمية
أعرض في EDS

Bariatric surgery, through beneficial effects on underlying mechanisms, improves cardiorenal and liver metabolic risk over an average of ten years of observation: A longitudinal and a case-control study.

التفاصيل البيبلوغرافية
العنوان: Bariatric surgery, through beneficial effects on underlying mechanisms, improves cardiorenal and liver metabolic risk over an average of ten years of observation: A longitudinal and a case-control study.
المؤلفون: Kokkinos A; First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece., Tsilingiris D; First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece., Simati S; First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece., Stefanakis K; First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; Department of Internal Medicine, Boston VA Healthcare System, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Angelidi AM; Department of Internal Medicine, Boston VA Healthcare System, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Tentolouris N; First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece., Anastasiou IA; First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece., Connelly MA; Labcorp, Morrisville, NC, USA., Alexandrou A; First Department of Surgery, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece., Mantzoros CS; Department of Internal Medicine, Boston VA Healthcare System, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: cmantzor@bidmc.harvard.edu.
المصدر: Metabolism: clinical and experimental [Metabolism] 2024 Mar; Vol. 152, pp. 155773. Date of Electronic Publication: 2024 Jan 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0375267 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-8600 (Electronic) Linking ISSN: 00260495 NLM ISO Abbreviation: Metabolism Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia, PA : W.B. Saunders
Original Publication: New York, Grune & Stratton.
مواضيع طبية MeSH: Bariatric Surgery* , Gastric Bypass* , Gastrointestinal Hormones* , Cardiovascular Diseases*/prevention & control , Obesity, Morbid*/surgery, Humans ; Case-Control Studies ; Proglucagon ; Obesity/surgery ; Liver ; Gastrectomy
مستخلص: Background: Bariatric surgery has long-term beneficial effects on body weight and metabolic status, but there is an apparent lack of comprehensive cardiometabolic, renal, liver, and metabolomic/lipidomic panels, whereas the underlying mechanisms driving the observed postoperative ameliorations are still poorly investigated. We aimed to study the long-term effects of bariatric surgery on metabolic profile, cardiorenal and liver outcomes in association with underlying postoperative gut hormone adaptations.
Methods: 28 individuals who underwent bariatric surgery [17 sleeve gastrectomy (SG), 11 Roux-en-Y gastric bypass (RYGB)] were followed up 3, 6 and 12 and at 10 years following surgery. Participants at 10 years were cross-sectionally compared with an age-, sex- and adiposity-matched group of non-operated individuals (n = 9) and an age-matched pilot group of normal-weight individuals (n = 4).
Results: There were durable effects of surgery on body weight and composition, with an increase of lean mass percentage persisting despite some weight regain 10 years postoperatively. The improvements in metabolic and lipoprotein profiles, cardiometabolic risk markers, echocardiographic and cardiorenal outcomes persisted over the ten-year observation period. The robust improvements in insulin resistance, adipokines, activin/follistatin components and postprandial gastrointestinal peptide levels persisted 10 years postoperatively. These effects were largely independent of surgery type, except for a lasting reduction of ghrelin in the SG subgroup, and more pronounced increases in proglucagon products, mainly glicentin and oxyntomodulin, and in the cardiovascular risk marker Trimethylamine-N-oxide (TMAO) within the RYGB subgroup. Despite similar demographic and clinical features, participants 10 years after surgery showed a more favorable metabolic profile compared with the control group, in conjunction with a dramatic increase of postprandial proglucagon product secretion.
Conclusions: We demonstrate that cardiorenal and metabolic benefits of bariatric surgery remain robust and largely unchanged ten years postoperatively and are associated with durable effects on gastrointestinal- muscle- and adipose tissue-secreted hormones.
Trial Registration: ClinicalTrials.gov: NCT04170010.
Competing Interests: Declaration of competing interest Ansh Labs contributed in kind (assay reagents). M.A.C is an employee of and holds stock in Labcorp. No other conflicts of interest pertaining to the work under consideration for publication were reported from the authors. Disclosures unrelated to this work follow: A.K. reports grants and advisory services for Novo Nordisk, advisory services for Elli Lilly, Bausch Health, Sanofi-Aventis, MSD, AstraZeneca, Elpen Pharmaceuticals, Boehringer-Ingelheim, Galenica, Ethicon and Epsilon Health. N.T. reports consultation fees from MSD, clinical trial fees from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Sanofi, and Novo Nordisk, and unrestricted grants from Eli Lilly, Boehringer Ingelheim, ELPEN, Libytec, and TrigoCare. A.A. reports a travelling fellowship to attend the 24th world congress of IFSO in Madrid, 3–7 September 2019 by Mavrogenis AE (local representative of Covidien). C.S.M. reports grants from Merck, AltrixBio, Coherus Biosciences, Novo Nordisk, and Boehringer Ingellheim through his Institution, personal fees and non-financial support from Ansh, AltrixBio, Coherus Biosciences, and Novo Nordisk, and personal fees from 89Bio, Lumos, GENFIT, Corcept, Intercept, Regeneron, CardioMetabolic Health Conference, The Metabolic Institute of America and Amgen. The other authors have nothing to report.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
References: Front Endocrinol (Lausanne). 2018 Nov 23;9:672. (PMID: 30532733)
J Biomed Res. 2011 Jul;25(4):266-73. (PMID: 23554700)
Nutrients. 2018 Oct 01;10(10):. (PMID: 30275434)
Metabolism. 2023 Oct;147:155655. (PMID: 37393945)
Surg Endosc. 2020 Mar;34(3):1048-1060. (PMID: 31745633)
N Engl J Med. 2002 May 23;346(21):1623-30. (PMID: 12023994)
Diabetes Care. 2021 Nov;44(11):2552-2563. (PMID: 34503954)
In Vivo. 2016 May-Jun;30(3):321-30. (PMID: 27107092)
Prog Mol Biol Transl Sci. 2014;121:23-65. (PMID: 24373234)
Endocrinology. 2021 Feb 1;162(2):. (PMID: 33165533)
JAMA Surg. 2021 Feb 1;156(2):137-146. (PMID: 33295955)
Obes Surg. 2012 May;22(5):740-8. (PMID: 22354457)
PLoS One. 2016 Sep 01;11(9):e0161425. (PMID: 27584017)
Metabolism. 2023 Nov;148:155689. (PMID: 37689110)
JAMA. 2018 Jan 16;319(3):255-265. (PMID: 29340679)
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6201-6206. (PMID: 31393567)
Obes Surg. 2021 Dec;31(12):5441-5445. (PMID: 34655054)
Diabetes Obes Metab. 2023 Sep;25(9):2561-2574. (PMID: 37246799)
Diabetes Obes Metab. 2019 Mar;21(3):683-690. (PMID: 30393997)
N Engl J Med. 2020 Oct 15;383(16):1535-1543. (PMID: 33053284)
Clin Res Cardiol. 2019 May;108(5):520-538. (PMID: 30298424)
Metab Syndr Relat Disord. 2016 May;14(4):197-201. (PMID: 27081744)
Surg Obes Relat Dis. 2021 Feb;17(2):444-455. (PMID: 33249084)
Obes Rev. 2007 May;8(3):253-61. (PMID: 17444966)
J Clin Endocrinol Metab. 2020 Apr 1;105(4):. (PMID: 32016415)
Lancet. 2021 May 15;397(10287):1830-1841. (PMID: 33965067)
Lancet. 2021 Jan 23;397(10271):293-304. (PMID: 33485454)
Obesity (Silver Spring). 2006 Feb;14(2):194-8. (PMID: 16571843)
Clin Nutr. 2023 Aug;42(8):1369-1378. (PMID: 37418844)
Metabolism. 2021 Feb;115:154441. (PMID: 33248063)
Metabolism. 2023 Jan;138:155346. (PMID: 36375643)
Diabetes Care. 2022 Feb 1;45(2):469-476. (PMID: 34857533)
Clin Nutr. 2021 Apr;40(4):1755-1766. (PMID: 33097305)
Nutr J. 2009 May 28;8:22. (PMID: 19476649)
Metabolism. 2022 Apr;129:155157. (PMID: 35114286)
Metabolism. 2019 Dec;101:153997. (PMID: 31672446)
N Engl J Med. 2012 Aug 23;367(8):695-704. (PMID: 22913680)
Obes Surg. 2020 Nov;30(11):4293-4299. (PMID: 32583298)
JAMA. 2018 Jan 16;319(3):241-254. (PMID: 29340676)
JAMA Surg. 2016 Nov 1;151(11):1046-1055. (PMID: 27579793)
Cold Spring Harb Perspect Biol. 2016 Jul 01;8(7):. (PMID: 27328872)
Front Pharmacol. 2015 Oct 05;6:218. (PMID: 26500551)
Metabolism. 2023 Nov;148:155692. (PMID: 37730085)
Metabolism. 2021 Jun;119:154773. (PMID: 33838144)
Science. 2021 Aug 13;373(6556):813-818. (PMID: 34385401)
Diabetes Metab Res Rev. 2020 Jul;36(5):e3297. (PMID: 32026536)
N Engl J Med. 2012 Apr 26;366(17):1567-76. (PMID: 22449319)
Obes Surg. 2013 Jan;23(1):31-8. (PMID: 22923313)
Atherosclerosis. 2001 Apr;155(2):517-23. (PMID: 11254924)
Atherosclerosis. 1996 Oct 25;126(2):277-87. (PMID: 8902153)
Diabetes. 2023 Mar 1;72(3):336-347. (PMID: 36478039)
Surg Obes Relat Dis. 2018 Jul;14(7):882-901. (PMID: 30077361)
Bioinformatics. 2018 Dec 15;34(24):4313-4314. (PMID: 29955821)
N Engl J Med. 2017 Sep 21;377(12):1143-1155. (PMID: 28930514)
Diabetes Obes Metab. 2021 Feb;23(2):489-498. (PMID: 33140542)
N Engl J Med. 2013 Apr 25;368(17):1575-84. (PMID: 23614584)
Surgery. 2018 Oct;164(4):774-783. (PMID: 30139560)
معلومات مُعتمدة: K24 DK081913 United States DK NIDDK NIH HHS
فهرسة مساهمة: Keywords: Bariatric surgery; Gut hormones; Obesity; Proglucagon-derived peptides
سلسلة جزيئية: ClinicalTrials.gov NCT04170010
المشرفين على المادة: 55963-74-1 (Proglucagon)
0 (Gastrointestinal Hormones)
تواريخ الأحداث: Date Created: 20240105 Date Completed: 20240207 Latest Revision: 20240218
رمز التحديث: 20240218
مُعرف محوري في PubMed: PMC10872266
DOI: 10.1016/j.metabol.2023.155773
PMID: 38181882
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-8600
DOI:10.1016/j.metabol.2023.155773